xerava
paion deutschland gmbh - eravacycline - infection; bacterial infections - antibacterials süsteemseks kasutamiseks, - xerava on näidustatud ravi keeruline intra-kõhuõõne infektsioonid (ciai) täiskasvanutel. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.
cresemba
basilea pharmaceutica deutschland gmbh - isavukonasool - aspergilloos - cresemba on näidustatud täiskasvanute raviks:invasiivsed aspergillosismucormycosis patsientidel, kellele amphotericin b on inappropriateconsideration tuleb arvestada ametlikke juhiseid sobiva kasutamise kohta seentevastased ained.
ganfort
abbvie deutschland gmbh & co. kg - bimatoprost, timolooli - glaucoma, open-angle; ocular hypertension - oftalmoloogilised vahendid - vähendada silmasisese rõhu (iop) koos avatud nurga glaukoomi või silma hüpertensiooniga patsientidel, kes ei allu piisavalt ravile lokaalse või prostaglandiini.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukeemia, lümfotsüütne, krooniline, b-rakk - antineoplastilised ained - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
xydalba
abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibacterials süsteemseks kasutamiseks, - Ägeda bakteriaalse naha ja naha struktuuri nakkuste (absssi) ravi täiskasvanutel.
ozurdex
abbvie deutschland gmbh & co. kg - deksametasoon - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex on näidustatud ravi täiskasvanud patsientidel, kellel macular turse pärast emb-kumb võrkkesta-veeni oklusioon (brvo) või kesk-võrkkesta-veeni oklusioon (crvo). ozurdex on näidustatud ravi täiskasvanud patsientidel, kellel on põletik tagumises segmendis silma esitades nagu noninfectious uveiit. ozurdex on näidustatud ravi täiskasvanud patsientidel, kellel on nägemispuudega tõttu diabeediga macular turse (dme), kes on pseudophakic või keda peetakse piisavalt vastuvõtlik, või ei sobi mitte-kortikosteroidide ravi.
viekirax
abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonaviiri - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - viekirax on näidustatud koos teiste kroonilise hepatiit c (chc) raviga ravitavate ravimitega täiskasvanutel. c-hepatiidi viiruse (hcv) genotüüp spetsiifiline aktiivsus.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosupressandid - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - unehäirete ja hoolduse häired - psühhoeptikumid - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.